Key EventApproval of director remuneration and re-appointment of three whole-time directors for 3-year terms starting February 2027.
ImpactThe company demonstrates strong financial recovery with improved profitability, targeted growth in high-potential segments, and shareholder-friendly dividend policy, supported by robust ESG practices and strategic capex plans.Sign up to read impact
Key EventTatva Chintan Pharma Chem Ltd filed its FY 2025-26 BRSR report with BSE and NSE on 27 August 2026.
ImpactThe company is actively advancing its ESG commitments with measurable targets on carbon, water, and supplier engagement, signaling long-term sustainability integration.Sign up to read impact